700-Patient study aims to unlock secrets of CAR-T success and failure

NCT ID NCT07609485

Recruiting now Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study collects blood and tumor samples from 700 adults receiving approved CAR-T therapy for blood cancers. Researchers will analyze these samples to identify biological markers that predict whether the therapy will work or if the cancer will return. The goal is to improve future CAR-T treatments by understanding why some patients respond well while others do not.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which patients will benefit most from CAR-T therapy and why some patients relapse.
What could go wrong: This is an observational study, not a treatment trial. It will not directly improve outcomes for participants and may not lead to new biomarkers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm leukemia lymphoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER HEMATOLOGIC MALIGNANCY

Contacts and locations

Locations

Hop Claude Huriez Chu Lille
TERMINATED

Lille, 59037, France
chu de Lille
RECRUITING

Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.